Organ Meats / Nose-to-Tail Nutrient Density

Overview

This video features Ronda Ayala, a nine-year survivor of pancreatic neuroendocrine cancer, and Maryann Wahmann, a neuroendocrine cancer patient and founder of the Neuroendocrine Cancer Awareness Network (NCAN). Ronda recounts her diagnosis, Whipple surgery, and the critical role Maryann played in encouraging her to maintain vigilant follow-up care.

Maryann shares her own experience with neuroendocrine cancer symptoms being initially misdiagnosed and the challenges patients face in receiving proper care. She founded the Whipple Warriors support group and NCAN to provide education and advocacy for patients with neuroendocrine tumors.

Key Points

• Ronda underwent Whipple surgery for pancreatic neuroendocrine cancer and was initially told she was cured.
• Maryann emphasized the necessity of ongoing follow-up, as neuroendocrine tumors can recur, which happened when Ronda’s cancer returned in her liver.
• They stress the importance of consulting neuroendocrine cancer specialists, as general oncologists may rarely encounter these tumors and their treatment differs significantly from other pancreatic cancers.
• Approximately 7% of pancreatic cancers are neuroendocrine tumors, underscoring the need for specialized knowledge and patient advocacy.
• The video highlights the supportive community formed through NCAN and Whipple Warriors, fostering connections and education among patients.

Source Information

This content is based on a 2 minute 48 second video titled "Ronda and Maryann -- She Saved My Life," published on YouTube by NCAN in 2020. The transcript provides a first-person account from both Ronda Ayala and Maryann Wahmann, detailing their personal experiences with neuroendocrine cancer, patient advocacy, and the importance of specialized follow-up care after surgery.

Overview

This video records a comprehensive panel discussion marking the launch of a new book on mistletoe therapy and its emerging role in integrative oncology. The contributors include physicians, naturopathic doctors, and researchers who share their personal journeys with mistletoe, clinical experiences, and the collaborative effort behind the book.

The discussion highlights mistletoe therapy as a botanical medicine used adjunctively with conventional cancer treatments, emphasizing individualized care, immune regulation, and the concept of "warmth" in healing. Panelists describe mistletoe’s historical and contemporary use, including subcutaneous and intravenous administration, and advanced applications such as intratumoral injections and fever therapy.

A significant portion of the conversation focuses on the recent Johns Hopkins phase one safety trial of intravenous mistletoe for advanced solid tumors, marking an important step in U.S.-based research. The panelists also address the challenges of funding large clinical trials due to mistletoe’s non-patentable status and summarize the existing European research supporting quality of life and immune benefits.

The panelists discuss mistletoe’s potential use during remission and as a preventive measure in high-risk individuals, while cautioning against indiscriminate use due to possible adverse reactions. They clarify the difference between acute, purposeful inflammation induced by mistletoe and harmful chronic inflammation.

Finding trained practitioners is noted as a challenge, with references to organizations such as Believe Big, Uriel Pharmacy, and the Physicians Association for Anthroposophic Medicine that support education and access. The book aims to serve as a bridge between patients and clinicians, and between conventional and integrative oncology, fostering a whole-person approach to cancer care.

Key Themes

• Collaborative Book Project: Created by a diverse group of experts to educate and support further research and clinical training in mistletoe therapy.
• Integrative Oncology: Mistletoe is presented as an adjunctive therapy complementing conventional cancer treatments, not a replacement.
• Research Landscape: Discussion of the Johns Hopkins intravenous mistletoe trial and decades of European studies on quality of life and immune support.
• Clinical Use and Individualization: Various administration routes, patient assessment, and the importance of practitioner training are emphasized.
• Immune Regulation and Warmth: Mistletoe’s role in stimulating acute immune responses and supporting immune surveillance is explored.
• Precautions: Use during pregnancy and preventive use are approached cautiously, highlighting the need for individualized medical judgment.
• Bridging Medical Traditions: The therapy fosters dialogue across naturopathic, anthroposophic, integrative, and conventional medical communities.

Source Information

This content is based on a 1 hour 21 minute video panel discussion titled "Mistletoe and the Emerging Future of Integrative Oncology: Book Launch!" published on YouTube on January 20, 2022. The discussion features multiple experts including Dr. Nasha Winters, ND, FABNO, Dr. Steven Johnson, DO, Dr. Mark Hancock, and others involved in the book project and clinical practice of mistletoe therapy.

The video includes detailed explanations of mistletoe therapy’s history, clinical protocols, research developments, and practical considerations for patients and practitioners. It also addresses frequently asked questions and highlights resources and organizations supporting mistletoe education and access.

For more information, the book is available through SteinerBooks and additional resources can be found at mistletoebook.com.